缬沙坦治疗早期糖尿病肾病的临床观察  

Clinical observation of angiotensin Ⅱ receptor antagonist on the treatment of earlier period of diabetes and kidney disease

作　　者：钟秀华[1] 李平[1] 黄志华[1] 

机构地区：[1]梅州市人民医院内科,广东省梅州514031

出　　处：《中国基层医药》2008年第8期1282-1283,共2页Chinese Journal of Primary Medicine and Pharmacy

摘　　要：目的观察血管紧张素Ⅱ受体拮抗剂缬沙坦应用对减少早期糖尿病肾病微量白蛋白尿的作用。方法36例早期糖尿病肾病患者使用缬沙坦80～160mg，每日1次，治疗8周，比较治疗前后血压、尿白蛋白量，并观察空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、内生肌酐清除率等变化。结果治疗后尿自蛋白明显下降（P〈0．01），而血压、空腹血糖、糖化血红蛋白、甘油三酯、总胆固醇、内生肌酐清除率无明显变化；治疗过程无明显不良反应。结论缬沙坦可减少尿白蛋白量，是治疗早期糖尿病肾病的有效药物之一。Objective To observe the application of angiotensin Ⅱ receptor antagonist valsartan in reducing minim albuminuria in earlier period of the diabetes and kidney disease. Methods 36 patients who administered angiotensin Ⅱ receptor antagonist valsartan 80 - 160mg,qd, for 8 weeks. Compared with symptoms before the treatment,the blood pressure, the amount of the urinary albuminuria, and observed the change of the empty stomach blood sugar, the saccharified hemoglobin, the triglyceride, the total cholesterol, the endogenous creatinine clearance rate, etc. Results After the treatment, the urinary albumin drops obviously（P 〈 0.01 ）, while the blood pressure, the empty stomach blood sugar, the saccharified hemoglobin, the triglyceride, the total cholesterol and the endogenous creatinine clearance rate have no obvious change. There is no obvious side effect during therapeutic process. Conclusion The application of angiotensin Ⅱ receptor antagonist valsartan can reduce the amount of the urinary albumin, is the effective way in treating the earlier period of the diabetes and kidney disease.

关 键 词：糖尿病肾病 受体 血管紧张素 临床分析 

分 类 号：R692[医药卫生—泌尿科学] R587[医药卫生—外科学]